
The U.K.’s National Institute for Health and Care Excellence (NICE) is recommending a treatment from a firm jointly owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE) and Shionogi Inc.
NICE has recommended ViiV Healthcare’s Apretude (cabotegravir) as a pre-exposure prophylaxis (PrEP) for individuals at high risk of HIV-1, marking it as the first injectable PrEP and the first to be appraised by NICE.